Capricor Therapeutics is cutting 10% of its staff to focus more on its main product, Deramiocel.

CAPR · Capricor Therapeutics

The AI's read

This leaves Capricor concentrating more effort on Deramiocel, which could make its work more focused. But other programs, including its exosome platform, are moving more slowly until regulators provide clearer answers. The staff cut and delays outweigh the possible benefit of a tighter focus.